A clinical-economic study of caspofungin use in the treatment of invasive candidiasis in intensive care units
Candida spp. are the fourth on the list of sepsis pathogens in patients in intensive care units. Currently the physician's armamentarium includes a whole range of antifungal medicines that have demonstrated high clinical-mycological effectiveness in clinical trials. The aim of this study to evaluate the clinical-economic usefulness of caspofungin therapy in the treatment of invasive candidiasis versus standard and alternative treatments in patients in intensive care units. The first time in the Russian clinical-economic analysis for targeted IC treatment in non-neutropenic patients in intensive care units who have not received primary prophylaxis with azole antimycotics, as well as in those with low (Candida spp. resistance to fluconazole according to national or local study results, yielded the following findings: the best strategy is initial amphotericin B therapy with subsequent switching to caspofungin in patients with ineffective initial amphotericin B therapy or those with severe adverse events.